Details of the Drug
General Information of Drug (ID: DMP70FI)
| Drug Name |
BIBT986
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
Tanogitran; UNII-X5QRR6Z56Q; X5QRR6Z56Q; CHEMBL1270156; Tanogitran [INN]; BIBT986; 637328-69-9; SCHEMBL2471738; MAOALPSHCIBFJZ-RUZDIDTESA-N; ZINC64527030; BDBM50328705; J3.538.630K; (R)-2-(4-Amidinophenylaminomethyl)-1-methyl-5-[l -(carboxymethylamino)-1-(pyrrolidinocarbonyl)-ethyl]-benzimidazole; (R)-2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1-(pyrrolidinocarbonyl) -ethyl]-benzimidazole
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 477.6 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | -1 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 9 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 5 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 7 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Thrombosis | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | DB61-GB90 | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References


